Bioscience

NeoPharm: A pipeline with multiple catalysts

October 2, 2009

By Flinn Foundation

[Source: One Med Place] – NeoPharm (OTC: NEOL.PK) is an emerging bio-pharmaceutical company focused on the development of anti-cancer agents based on two proprietary technology platforms that include tumor-targeting toxins and a NeoLipid drug delivery system, which encapsulates hard-to-deliver chemotherapy drugs in a fat (lipid) membrane for preferential uptake by tumors and a more stable product formulation. NeoPharm has advanced five drug product candidates into various stages of clinical and pre-clinical development for the treatment of cancer in addition to one drug product candidate in pre-clinical development for lung conditions (pulmonary fibrosis and asthma).

For more information: NeoPharm: A Pipeline with Multiple Catalysts